Clinical Trials Browser

Phase 2 × Erlotinib Hydrochloride × Clear all

NCT06997068 2026-04-17

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

Mouth Neoplasms

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2 Active not recruiting

50 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT04981509 2026-04-07

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01897480 2026-01-26

Balise

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00602667 2026-01-13

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Phase 2 Active not recruiting

293 enrolled 89 charts

Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor

NCT01708954 2025-11-28

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

125 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01927744 2025-11-26

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Phase 2 Completed

55 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT04172779 2025-11-20

ECHO-B

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT01186861 2025-11-18

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01221077 2025-11-18

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00977470 2025-10-15

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Phase 2 Active not recruiting

76 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05442060 2025-08-03

EGFR

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Phase 2 Completed

17 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Phase 2 Completed

83 enrolled 17 charts

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT01032070 2024-12-12

PETEY

Phase 2 Terminated

25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Phase 2 Terminated

4 enrolled 9 charts

Familial ependymoma, Ependymoma

NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Phase 2 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Phase 2 Completed

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT00720304 2024-08-22

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

43 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT01064479 2024-07-16

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

123 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01174043 2023-10-13

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Phase 2 Completed

11 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Myelomonocytic, Acute

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT00750698 2023-07-06

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2 Terminated

8 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

123 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT05904457 2023-06-15

BRISK

Phase 2 Unknown

Neoplasm Metastasis, Neoplasms

NCT00597597 2023-05-17

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Phase 2 Terminated

11 enrolled 12 charts

Breast Neoplasms

NCT01180959 2022-11-07

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Phase 2 Completed

45 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01562028 2022-08-24

BELIEF

Phase 2 Completed

109 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Phase 2 Completed

46 enrolled 13 charts

Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli

NCT00553800 2022-07-12

NSCLC

Phase 2 Completed

32 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT03086538 2022-06-15

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms

NCT03110484 2022-06-15

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT02748707 2022-04-28

ERLO-XIB

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT01470716 2022-04-06

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03126799 2022-04-06

AvaTa

Phase 2 Unknown

EGFR Positive Non-small Cell Lung Cancer

NCT00600015 2022-03-10

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

166 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT00393068 2022-03-02

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2 Completed

62 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms